Convulex®

Convulex®

Convulex® contains the active substance sodium valproate.

Convulex® is a medicinal product for the treatment of seizure disorders (antiepileptic drug). 

Enteric-coated capsules, oral solution:

Epilepsies: for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Bipolar disorders: for the treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continued treatment after a manic episode may be considered in those patients who have responded to valproate therapy for acute mania.

Migraine: for prophylaxis of migraine attacks when other medicines for migraine are not sufficiently effective.

Prolonged-release tablets:

Epilepsies: for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Bipolar disorders: for the treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continuing treatment after a manic episode may be considered in patients who have responded to valproate in the treatment of acute mania.

Syrup:

Epilepsies: Convulex® 50 mg/ml syrup for children is used for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Solution for injection:

For the treatment of epileptic seizures and manic episodes in bipolar disorder when oral administration of sodium valproate is not suitable or temporarily not possible.

Also effective for:

  • generalised seizures in the form of absences, myoclonic seizures, tonic-clonic seizures, atonic seizures and mixed seizure types,
    Focal seizures in the form of simple or complex seizures, secondary generalised seizures and specific syndromes (West syndrome, Lennox-Gastaut syndrome).
  • Treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continued treatment after a manic episode may be considered in those patients who have responded to valproate therapy for acute mania.

In young children, sodium valproate is the drug of first choice only in exceptional cases; Convulex® solution for injection should be used only with special caution after a strict risk-benefit assessment and, if possible, as monotherapy.

Officially instructed educational material Valproate

 

Активна субстанция: Valproinsäure/Natriumvalproat

Концентрация в една дозова единица Размер на опаковката (брой дозови единици)
150 mg 100
300 mg 100
500 mg 100
300 mg 50
500 mg 50
300 mg/ml 100 ml
50 mg/ml 100 ml
100 mg/ml 5 capsules (à 5 ml)

Изтегляния

Информация за лекари и фармацевти

Референтен продукт: Convulex®

The anticonvulsant valproic acid activates glutamic acid decarboxylase and simultaneously inhibits GABA transaminase. This greatly increases the content of GABA in the synaptosomes and in the intersynaptic cleft. As an inhibitory neurotransmitter, GABA inhibits pre- and postsynaptic discharges and thus prevents the spread of seizure activity. A number of placebo-controlled clinical studies have also demonstrated good and rapid efficacy in the treatment of manic phases in patients with bipolar disorder. Furthermore, the efficacy of valproate in the prophylaxis of migraine attacks has been demonstrated in several placebo-controlled double-blind studies.1

Valproic acid (e.g. Convulex®) is recommended by the DGE guidelines as a group I anticonvulsant for focal epilepsies and for idiopathic generalised epilepsies. Especially in idiopathic generalised epilepsies, valproate is indispensable according to the guidelines.2

The five lactose-free dosage forms of Convulex® allow individualised therapy to ensure compliance of the respective patient:

Convulex® solution for injection can be used immediately without further preparation. Rapid use can be particularly important in situations where oral administration of valproic acid is not suitable or not possible. The divisible Convulex® sustained-release tablets (300 and 500 mg) and Convulex® capsules (150, 300 and 500 mg) release the active substance specifically in the intestine. For patients with swallowing difficulties, Convulex® orange-flavoured oral solution can be an alternative. Especially for children with epilepsy, Convulex® is available as a syrup (sugar-free, gentle on teeth) with raspberry-peach flavouring.1

 

1 SmPC Convulex® gastro-resistant capsules, Convulex® oral solution, Convulex® syrup for children, Convulex® ampoules. Status of information: January 2022; SmPC Convulex® prolonged release tablets. Status of information: May 2022.
2 Baumgarter G. et al. Guideline first epileptic seizure and epilepsies in adulthood. German Society of Neurology (ed.), Georg Thieme Verlag, 2012.